Group 1 - The National Health Commission of China has issued notifications prohibiting the use of "ileal-jejunal anastomosis" for the treatment of type 2 diabetes and "cervical deep lymphatic vessel/lymph node-venous anastomosis" for Alzheimer's disease treatment [2][3] - The cervical deep lymphatic vessel/lymph node-venous anastomosis is primarily used for treating stubborn lymphedema, but its application for Alzheimer's disease lacks clear indications and contraindications, as well as high-quality evidence supporting its safety and efficacy [2] - The ileal-jejunal anastomosis, used for restoring intestinal continuity, has been deemed to lack foundational theoretical support and high-quality evidence for its safety and efficacy in treating type 2 diabetes [3] Group 2 - The domestic anastomosis device market may be impacted by these prohibitions, with the top 10 manufacturers in China including Johnson & Johnson, Covidien, Frankmann, Yisi Medical, Tianchen Medical, Palt Medical, David Medical, Rich Surgical, Yintukang Medical, and Brolansense [3] - Relevant listed companies in this sector include Dongxing Medical and Tianchen Medical, which may face challenges due to the new regulations [3]

Core Viewpoint - The National Health Commission of China has issued two important notifications prohibiting the use of specific surgical techniques for treating Alzheimer's disease and type 2 diabetes due to safety and efficacy concerns [2][4][5]. Group 1: Prohibition of Surgical Techniques - The "cervical deep lymphatic vessel/lymph node-venous anastomosis" technique is prohibited for Alzheimer's treatment as it is still in the early exploratory stage of clinical research, lacking clear indications and contraindications, and high-quality evidence for safety and efficacy [4]. - The "jejunum-ileum anastomosis" technique is banned for type 2 diabetes treatment due to uncertain safety and efficacy, with potential severe complications such as liver failure and malnutrition [5]. Group 2: Regulatory Actions - Local health administrative departments are required to ensure that medical institutions cease the use of the prohibited techniques for the specified conditions and provide follow-up services for affected patients [4][5]. - The National Health Commission will guide qualified medical institutions to strengthen clinical research design once sufficient preclinical research evidence is available, and will reassess the clinical application of these techniques based on research outcomes [4].